The question I get most often, once a woman has decided to start estrogen, is not whether she should do it — she has usually been working on that decision for a year or two. The question is which route. Patch, pill, pellet, cream, gel, troche. The marketing is loud, the research is mixed depending on which study you read, and the patient sitting across from me has usually heard a different story from every friend, sister, and influencer she has consulted before walking in. I want to take this apart the same way I take it apart in the consultation room.
Delivery route matters because estrogen does not behave the same in the body depending on how it gets there. The same milligram of estradiol delivered through the skin produces a fundamentally different physiological response than the same milligram swallowed. That is biochemistry, and ignoring it is how patients end up on the wrong protocol for years.
Why the route changes the drug
When you swallow estradiol, it goes through what we call first-pass hepatic metabolism. The pill is absorbed in the gut, dumped straight into portal circulation, and runs through the liver before any of it reaches the rest of the body. The liver does two things with that bolus: it metabolizes a large fraction of the estradiol into estrone and estrone sulfate (less biologically useful forms), and it reads "high estrogen" and ramps up production of clotting factors, sex hormone binding globulin (SHBG), and several inflammatory proteins.
That last part is the issue. Elevated SHBG binds free testosterone, which is why women on oral estrogen sometimes complain that their libido tanked even though their estradiol level looks fine on paper. Elevated clotting factors are why oral estrogen carries the venous thromboembolism risk that transdermal estrogen largely does not. The Women's Health Initiative — the study that scared a generation of women off hormones — used oral conjugated equine estrogen. That matters. The risk profile of a transdermal estradiol patch in a 52-year-old woman without contraindications looks nothing like the risk profile of Premarin in the WHI cohort.
Transdermal delivery — patches, gels, creams — bypasses the liver. Estradiol crosses the skin, enters systemic circulation directly, and reaches receptors at the dose you would expect from the dose you applied. SHBG does not climb the way it does with oral. Clotting factor changes are minimal. The estradiol-to-estrone ratio stays closer to what your ovaries used to produce.
Pellets are also a transdermal-equivalent route in the sense that they bypass the gut — they release estradiol from a subcutaneous depot directly into systemic circulation over three to five months. Different kinetics, same physiological logic.
The patch — what I reach for first in most women
When I evaluate a woman in her late forties or early fifties presenting with classic perimenopausal or postmenopausal symptoms — vasomotor instability, sleep that fell apart somewhere around age 47, brain fog, joint aches, mood that no longer recovers from a hard day — and her labs and history support hormone optimization, the estradiol patch is usually where I start. Specifically, a twice-weekly transdermal estradiol patch dosed to deliver somewhere in the 0.025 to 0.075 mg/day range, titrated based on response and follow-up labs.
Reasons I lean here:
- Steady serum levels. Patches deliver estradiol in a near-physiologic continuous release pattern. No daily peak-and-trough swings.
- Bypasses first-pass metabolism. SHBG stays normal. Clotting risk stays low.
- Easy to titrate. If she is undershooting, I move from a 0.05 to a 0.075 patch. If she is overshooting, the reverse. Dose changes show up in the labs at four to six weeks.
- Easy to stop. If something changes — new diagnosis, surgery coming up, side effect — she peels off the patch and serum estradiol drops in 24 to 48 hours. That is not true of a pellet.
The downsides are honest ones. Some patients have skin reactions to the adhesive. Patches can lift off in the Georgia summer if you are sweating through them at the gym or working outside in July (Columbus and Warner Robins both deliver months where this becomes a practical issue). And not every pharmacy in middle Georgia stocks the dose I want, which means we sometimes route through a comprehensive lab work partner pharmacy to keep the supply consistent.
Oral estradiol — when I actually use it
Oral estradiol is not off the table, but it is rarely my first choice in a peri- or postmenopausal woman. The patients I do put on oral are usually women who specifically cannot tolerate transdermal — adhesive allergy that we cannot work around with gel, or skin conditions in the application zones — and who do not have personal or family history of clotting disease, migraine with aura, or active gallbladder disease.
Even then, I tend to use oral estradiol (not conjugated equine estrogen) and pair it with the right form of progesterone. Oral micronized progesterone at bedtime is its own conversation, and an important one — the progesterone you pair with estrogen materially changes the safety profile of the whole protocol. I have written about that elsewhere; it is worth reading before you commit to a regimen.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Use the Start Here PathwayPellets — the most misunderstood option
Biote pellet therapy has a polarized reputation among clinicians, mostly because it has been used badly in some practices. Used well, pellets are an excellent option for the right patient. Used poorly — wrong dose, wrong patient selection, no follow-up labs — they produce supraphysiologic estradiol levels for months at a time with no way to dial back. That is where the bad reputation came from, and it was deserved in those cases.
The patients I tend to recommend pellets for are women who have already established that they respond to estrogen, who hate the daily-ritual aspect of patches or creams, who travel frequently and find compliance hard with topical regimens, and whose physiology has shown a stable, predictable response on a transdermal trial first. I do not put a brand-new hormone patient on pellets until I know how her body handles estrogen. A three-to-six-month transdermal trial gives me that information cheaply.
The mechanics: a small estradiol pellet (often combined with a testosterone pellet) is inserted under the skin of the upper buttock through a tiny incision. It releases hormone steadily over three to five months. No daily dosing. No patch falling off in the heat. Levels stay smooth.
The honest downside: once it is in, it is in. If the dose is wrong, you are managing that dose for the next three months. This is why I dose conservatively the first time and reassess at six to eight weeks with serum estradiol to confirm we are in the range I expected.
What I look for in choosing a route
When a patient sits down with her labs in front of us, the route question is not abstract. I am thinking about a specific list:
- Personal and family history of VTE, stroke, MI. If any of that is in the picture, transdermal — patch, gel, cream, or pellet — is the answer. Not oral.
- Migraine with aura. Same answer. Avoid oral. The vascular risk profile of transdermal is substantially lower.
- Triglycerides and lipid pattern. Oral estrogen raises triglycerides. In a woman who already has elevated triglycerides or metabolic syndrome, that is a meaningful nudge toward transdermal.
- Liver function and gallbladder history. Oral estrogen is a problem here. Transdermal sidesteps it.
- SHBG on her baseline panel. If SHBG is already high (which suppresses free testosterone and contributes to low-libido symptoms), oral estrogen will make that worse. Transdermal will not.
- Lifestyle and compliance. The route a patient will actually use beats the route that looks best on paper. A woman who will forget a daily gel will do better on a twice-weekly patch or a quarterly pellet.
- Goals beyond estrogen. If she also needs testosterone — and a meaningful percentage of women in this age range do — pellets allow combined dosing in a single insertion. That is a real convenience advantage.
After 17 years of clinical practice across emergency medicine and now hormone work, the pattern I see is that delivery route is one of the highest-leverage decisions in the protocol. The difference between a woman who feels like herself again at three months and a woman who is back in my office complaining of new symptoms often comes down to whether the route matched her physiology.
Progesterone is part of the route conversation
I would be doing this article wrong if I did not mention progesterone. Any woman with a uterus on estrogen needs progesterone to protect the endometrium — that is non-negotiable. The form of progesterone matters as much as the form of estrogen. Oral micronized progesterone at bedtime is what I use in most cases because it has the additional benefit of GABAergic sleep effects, which is helpful since perimenopausal sleep disruption is one of the most common reasons women come to see me in the first place. Synthetic progestins (medroxyprogesterone, norethindrone) do not offer that benefit and have their own metabolic baggage.
The estrogen-progesterone combination is the protocol. Treating estrogen alone in a woman with a uterus is not appropriate, and treating progesterone alone is rarely the right move either. The two work together.
Your next step
If you have read this far, you are probably trying to decide whether to start the conversation. Here is what that actually looks like in my practice. Book a consultation at either the Columbus location or the Warner Robins location — protocol is the same at both, I rotate between them, and you can use whichever drive is shorter. Bring any labs from the past 12 months. If you do not have recent labs, we will order a full panel at the first visit: estradiol, progesterone, total and free testosterone, DHEA-S, SHBG, full thyroid (TSH, free T3, free T4, reverse T3, antibodies), metabolic markers, hs-CRP.
The lab review visit is where the route decision actually gets made. You will see your numbers, I will explain what each one is telling us about your physiology, and we will pick a route together based on what fits your body, your history, your lifestyle, and your goals. Patch, pill, pellet, gel — none of these is universally right. The right one is the one that matches you. If you want to start by checking where you are symptomatically, the hormone health assessment is a reasonable place to begin before you book a consultation.
*Information in this article is educational and does not constitute medical advice. Consultation and lab work are required before any hormone therapy is recommended. Individual results vary.*
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
